Trial reportBritish journal of clinical pharmacology2005
Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
Trial report in British journal of clinical pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Does ergogenic effect of caffeine supplementation depend on CYP1A2 genotypes? A systematic review with meta-analysis.Journal of sport and health science · 2024Pooled it
- Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.Clinical pharmacokinetics · 2007Trial
- An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.European journal of drug metabolism and pharmacokinetics · 2025Review
- Metabolite Measurement in Index Substrate Drug Interaction Studies: A Review of the Literature and Recent New Drug Application Reviews.Metabolites · 2024Review
- The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.European journal of drug metabolism and pharmacokinetics · 2024Review
- Neuroprotective Effect of Caffeine in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2022Review
- Fluvoxamine for symptomatic outpatients with COVID-19.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022Review
- Caffeine Enhances the Balance System and Postural Balance in Short Time in Healthy Individuals.Turkish archives of otorhinolaryngology · 2021Article
- A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.Clinical pharmacology in drug development · 2021Article
- Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.Frontiers in pharmacology · 2021Review
- Article
- Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.Journal of clinical pharmacology · 2019Article
- Predictive Value of Microdose Pharmacokinetics.Clinical pharmacokinetics · 2019Review
- Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.Drug metabolism and disposition: the biological fate of chemicals · 2019Article
- Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.CPT: pharmacometrics & systems pharmacology · 2019Article
- Mechanisms and the clinical relevance of complex drug-drug interactions.Clinical pharmacology : advances and applications · 2018Review
- Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Clinical pharmacology and therapeutics · 2014Article
- Predicting drug candidate victims of drug-drug interactions, using microdosing.Clinical pharmacokinetics · 2012Article
- High Blood caffeine levels in MCI linked to lack of progression to dementia.Journal of Alzheimer's disease : JAD · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCoadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine. The clinical importance of this interaction is not established.
aimTo evaluate the effects of fluvoxamine on the kinetics and dynamics of single doses of caffeine.
methodsSeven healthy subjects received single 250 mg doses of caffeine (or matching placebo) together with fluvoxamine (four doses of 100 mg over 2 days) or with matching placebo in a double-blind, four-way crossover study. For 24 h after caffeine or placebo administration, plasma caffeine and fluvoxamine concentrations were determined. Psychomotor performance, sedation, and electroencephalographic (EEG) "beta" frequency activity were also assessed.
resultsFluvoxamine significantly reduced apparent oral clearance of caffeine (105 vs. 9.1 mL min(-1), P < 0.01; mean difference: 95.7 mL min(-1), 95% CI: 54.9-135.6), and prolonged its elimination half-life (4.9 vs. 56 h, P < 0.01; mean difference: 51 h, 95% CI: 26-76). Caffeine produced CNS-stimulating effects compared with placebo. However, psychomotor performance, alertness, or EEG effects attributable to caffeine were not augmented by coadministration of fluvoxamine.
conclusionsFluvoxamine greatly impaired caffeine clearance, but without detectable changes in caffeine pharmacodynamics. However, this study does not rule out possible adverse effects due to extensive accumulation of caffeine with daily ingestion in fluvoxamine-treated individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.